KellyD.StoneMD
Allergy & Immunology • Washington, DCDirector, Allergy and Immunology Clinical Fellowship Program, NIH, NIAID
Are you Dr. Stone?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
111 Michigan Ave Nw
111 Michigan Avenue, Nw
Washington, DC 20010Phone+1 202-884-4013
Summary
- Dr. Kelly Stone, MD is an allergist/immunologist in Washington, District of Columbia. He is currently licensed to practice medicine in Maryland. He is a Director at NIH.
Education & Training
Boston Children’s HospitalFellowship, Allergy and Immunology, 2001 - 2003
Children's National HospitalResidency, Pediatrics, 1998 - 2001
University of Maryland School of MedicineClass of 1998
Certifications & Licensure
MD State Medical License 2004 - 2025- American Board of Allergy and Immunology Allergy & Immunology
Clinical Trials
- Screening Protocol for Genetic Diseases of Allergic Inflammation Start of enrollment: 2010 Nov 02
- Natural History of Severe Allergic Inflammation and Reactions Start of enrollment: 2010 Jul 12
Publications & Presentations
PubMed
- 95 citationsHematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human TH2 cell subpopulation with enhanced functionAlyssa Mitson-Salazar, Yuzhi Yin, Daniel L. Wansley, Michael Young, Hyejeong Bolan
The Journal of Allergy and Clinical Immunology. 2016-03-01 - 165 citationsAutosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairmentYu Zhang, Xiaomin Yu, Mie Ichikawa, Jonathan J. Lyons, Shrimati Datta
The Journal of Allergy and Clinical Immunology. 2014-05-01 - 243 citationsIgE, mast cells, basophils, and eosinophils.Kelly D Stone, Calman Prussin, Dean D Metcalfe
The Journal of Allergy and Clinical Immunology. 2010-02-01
Press Mentions
FDA Approves 1st Needle-Free Alternative to EpiPensAugust 12th, 2024- FDA Approves Neffy as First Needle-Free Nasal Spray for AnaphylaxisAugust 12th, 2024
- FDA Approves First Nasal Spray for Emergency Treatment of Serious Allergies Including AnaphylaxisAugust 11th, 2024
- Join now to see all
